Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

, JUNO

Juno Therapeutics

$20.05

-1.08 (-5.11%)

08:27
12/01/16
12/01
08:27
12/01/16
08:27

bluebird bio data looks 'impressive,' says Leerink

Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.

BLUE

bluebird bio

$60.35

-4.05 (-6.29%)

JUNO

Juno Therapeutics

$20.05

-1.08 (-5.11%)

KITE

Acquired by GILD 9/17

$50.93

1.92 (3.92%)

NVS

Novartis

$68.76

-0.2 (-0.29%)

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

BLUE bluebird bio
$60.35

-4.05 (-6.29%)

11/29/16
PIPR
11/29/16
NO CHANGE
PIPR
Piper sees bluebird regaining 'mojo and momentum'
After hosting management for an investor dinner, Piper Jaffray analyst Joshua Schimmer sees bluebird bio regaining its "mojo and momentum." The analyst expects a "steady stream of positive updates and derisking" starting with BCMA CAR-T data update this week and extending into optimizing LentiGlobin's profile for sickle cell and betathal in 2017. Schimmer has an Overweight rating on bluebird shares with a $95 price target. The biotechnology company closed yesterday down 5% to $60.65.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
12/01/16
WELS
12/01/16
NO CHANGE
WELS
bluebird bio data positive, says Wells Fargo
After bluebird bio announced interim Phase 1 dose escalation data for its CAR T product bb2121 in patients with relapsed/refractory multiple myeloma, Wells Fargo says the data shows that the product provides "a profound benefit for patients exhausting available treatment options." Wells thinks that the product could be approved on an accelerated timetable, and it keeps an Outperform rating on the stock.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
JUNO Juno Therapeutics
$20.05

-1.08 (-5.11%)

11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/25/16
11/25/16
DOWNGRADE
Target $25

Hold
Juno Therapeutics downgraded to Hold at SunTrust
As previously reported, SunTrust analyst Peter Lawson downgraded Juno Therapeutics to Hold from Buy due to the reduced visibility and increased uncertainty that comes from the two additional deaths in the company's ROCKET trial of JCAR015. Citing the renewed issues with JCAR015, Lawson decreased his probability of success across the company's pipeline and lowered his price target for Juno shares to $25 from $48.
KITE Acquired by GILD 9/17
$50.93

1.92 (3.92%)

10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
NVS Novartis
$68.76

-0.2 (-0.29%)

10/26/16
LEER
10/26/16
NO CHANGE
Target $80
LEER
Market Perform
Novartis price target lowered to $80 from $89 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Novartis to $80 from $89 after a "disappointing" Q3 performance despite bottom-line beat. The analyst reiterates a Market Perform rating on the shares.
11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change  »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.